Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria

Sept 22 (Reuters) - Vertex Pharmaceuticals Incorporated VRTX.O:

• VERTEX ANNOUNCES POSITIVE RESULTS FROM PHASE 2B AMPLIFIED STUDY OF INAXAPLIN IN ADDITIONAL POPULATIONS OF PEOPLE WITH APOL1-MEDIATED KIDNEY DISEASE (AMKD) AND COMPLETION OF ENROLLMENT IN THE PHASE 2/3 AMPLITUDE TRIAL

• VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -42.7% AT WEEK 13 IN AMKD WITH MODEST PROTEINURIA

• VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN REDUCES UACR BY -17.3% AT WEEK 13 IN AMKD WITH TYPE 2 DIABETES

• VERTEX PHARMACEUTICALS INCORPORATED - INAXAPLIN GENERALLY SAFE AND WELL TOLERATED IN BOTH AMKD COHORTS

Further company coverage: VRTX.O